Transcatheter aortic valve implantation for severe aortic stenosis - a new paradigm for multidisciplinary intervention: A prospective cohort study

被引:55
作者
Dworakowski, Rafal [1 ]
MacCarthy, Philip A. [1 ]
Monaghan, Mark [1 ]
Redwood, Simon [1 ]
El-Gamel, Ahmed [1 ]
Young, Christopher [1 ]
Bapat, Vinayat [1 ]
Hancock, Jane [1 ]
Wilson, Karen [1 ]
Brickham, Beth [1 ]
Wendler, Olaf [1 ]
Thomas, Martyn R. [1 ]
机构
[1] Kings Coll Hosp London, Dept Cardiol, Cardiac Unit, Kings Hlth Partners, London SE5 9RS, England
关键词
HIGH-RISK PATIENTS; REPLACEMENT; SOCIETY;
D O I
10.1016/j.ahj.2010.05.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Transcatheter aortic valve implantation (TAVI) is an alternative treatment option for patients with aortic stenosis deemed high risk or unsuitable for aortic valve replacement. The aim of this study was to assess the feasibility of TAVI in elderly patients, the delivery of this technology with a multidisciplinary approach, and the use of traditional surgical scoring systems. Methods One hundred fifty-one consecutive patients (mean age 82.6 +/- 7.3 years) with severe aortic stenosis underwent TAVI with the Edwards Lifesciences (Irvine, CA) Sapien bioprosthesis using the transapical (n = 84; 56%) or transfemoral (n = 67; 44%) approach from August 2007 to September 2009 at King's Health Partners, London, United Kingdom. We analyzed procedural outcome, complications, functional status, and midterm outcome of patients. Results The multidisciplinary team comprised interventional cardiologists, cardiothoracic surgeons, imaging specialists, cardiac anesthetists, and specialist nurses. Seventy percent of patients were in New York Heart Association class III/IV, and logistic EuroSCORE was 21.6 +/- 11.9. Procedural success was achieved in 98%. Postoperative complications included stroke (6%), complete atrioventricular block (5.3%), renal failure requiring hemofiltration (9.3%), and vascular injury (8.6%). Overall 30-day mortality was 9.9% (n = 15). The logistic EuroSCORE was a predictor of short-term mortality (logistic regression model, P < .05). Thirty-day mortality post-TAVI for patients with logistic EuroSCORE <20, 20 to 40, and >40 was 5.4%, 13.2%, and 22.2%, respectively. Conclusions Transcatheter aortic valve implantation is a feasible treatment option in this patient group with promising short/medium-term results. Renal failure is the commonest short-term complication, and the incidence of vascular complications remains high. Risk prediction/case selection remains challenging, and a multidisciplinary team approach appears to be helpful in appropriate patient selection. (Am Heart J 2010;160:237-43.)
引用
收藏
页码:237 / 243
页数:7
相关论文
共 14 条
[1]   Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction [J].
Bonhoeffer, P ;
Boudjemline, Y ;
Saliba, Z ;
Merckx, J ;
Aggoun, Y ;
Bonnet, D ;
Acar, P ;
Le Bidois, J ;
Sidi, D ;
Kachaner, J .
LANCET, 2000, 356 (9239) :1403-1405
[2]   Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis - First human case description [J].
Cribier, A ;
Eltchaninoff, H ;
Bash, A ;
Borenstein, N ;
Tron, C ;
Bauer, F ;
Derumeaux, G ;
Anselme, F ;
Laborde, F ;
Leon, MB .
CIRCULATION, 2002, 106 (24) :3006-3008
[3]   Treatment of calcific aortic stenosis with the percutaneous heart valve - Mid-term follow-up from the initial feasibility studies: The French experience [J].
Cribier, A ;
Eltchaninoff, H ;
Tron, C ;
Bauer, F ;
Agatiello, C ;
Nercolini, D ;
Tapiero, S ;
Litzler, PY ;
Bessou, JP ;
Babaliaros, V .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (06) :1214-1223
[4]   High-Risk Patients Referred for Transcatheter Aortic Valve Implantation: Management and Outcomes [J].
Dewey, Todd M. ;
Brown, David L. ;
Das, Tony S. ;
Ryan, William H. ;
Fowler, Jill E. ;
Hoffman, Shannon D. ;
Prince, Syma L. ;
Herbert, Morley A. ;
Culica, Dan ;
Mack, Michael J. .
ANNALS OF THORACIC SURGERY, 2008, 86 (05) :1450-1457
[5]   A prospective survey of patients with valvular heart disease in Europe:: The Euro Heart Survey on Valvular Heart Disease [J].
Iung, B ;
Baron, G ;
Butchart, EG ;
Delahaye, F ;
Gohlke-Bärwolf, C ;
Levang, OW ;
Tornos, P ;
Vanoverschelde, JL ;
Vermeer, F ;
Boersma, E ;
Ravaud, P ;
Vahanian, A .
EUROPEAN HEART JOURNAL, 2003, 24 (13) :1231-1243
[6]  
Lung B, 2007, CURR PROB CARDIOLOGY, V32, P609, DOI 10.1016/j.cpcardiol.2007.07.002
[7]   Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans [J].
Miller, Jordan D. ;
Chu, Yi ;
Brooks, Robert M. ;
Richenbacher, Wayne E. ;
Pena-Silva, Ricardo ;
Heistad, Donald D. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (10) :843-850
[8]   Burden of valvular heart diseases: a population-based study [J].
Nkomo, Vuyisile T. ;
Gardin, Julius M. ;
Skelton, Thomas N. ;
Gottdiener, John S. ;
Scott, Christopher G. ;
Enriquez-Sarano, Maurice .
LANCET, 2006, 368 (9540) :1005-1011
[9]   Relationship between the logistic EuroSCORE and the Society of Thoracic Surgeons Predicted Risk of Mortality score in patients implanted with the CoreValve ReValving System-A Bern-Rotterdam Study [J].
Piazza, Nicolo ;
Wenaweser, Peter ;
van Gameren, Menno ;
Pilgrim, Thomas ;
Tsikas, Apostolos ;
Otten, Amber ;
Nuis, Rutger ;
Onuma, Yoshinobu ;
Cheng, Jin Ming ;
Kappetein, A. Pieter ;
Boersma, Eric ;
Juni, Peter ;
de Jaegere, Peter ;
Windecker, Stephan ;
Serruys, Patrick W. .
AMERICAN HEART JOURNAL, 2010, 159 (02) :323-329
[10]  
Ross J Jr, 1968, Circulation, V38, P61